AMGN241206C375000
- 0.31
- 0.000.00%
Amgen Newsroom
Fresh Closing Highs from S&P 500 and Nasdaq | Wall Street Today
Express News | 'ADA Advises Against Using Compounded GLP-1 RA Medications' - Medscape
Tuesday S&P 500 Pulls Back From Highs, Nasdaq Climbs | Live Stock
Sector Update: Health Care Stocks Decline Premarket Tuesday
Weight Loss Drug Wars Heat Up: Amgen Challenges Eli Lilly, Novo's Dominance
Sector Update: Health Care
Coherus BioSciences to Divest Udenyca to Intas Pharmaceuticals for Up to $558 Million
S&P 500 and Nasdaq Hit Closing and Trading Highs Monday | Wall Street Today
10 Health Care Stocks With Whale Alerts In Today's Session
December Starts With a Mixed Market | Live Stock
Amgen, Nike Share Losses Lead Dow's 115-Point Drop
Evercore Maintains Amgen(AMGN.US) With Buy Rating
TD Cowen Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $383
TD Cowen Reaffirms Their Buy Rating on Amgen (AMGN)
Express News | Amgen : Deutsche Bank Cuts Target Price to $285 From $305
AMGEN TO PRESENT AT CITI'S 2024 GLOBAL HEALTHCARE CONFERENCE
The strongest competitor's data is not good, will the 'weight-loss duo' continue to dominate?
Analysts believe that if Amgen's weight loss drug could achieve a 20% weight loss effect a few years ago, it would have been the best among similar products, but now Eli Lilly and Co and Novo-Nordisk A/S pipeline drugs may achieve or exceed a 25% weight loss effect. Currently, dozens of pharmaceutical companies are actively entering the weight loss drug market, but none have shown the potential to truly challenge the 'weight loss giants'.
Amgen Inc. (AMGN): A Bull Case Theory
Eli Lilly and Novo Nordisk's Obesity Moat Just Got Stronger -- Heard on the Street -- WSJ
Boeing, NVIDIA Corp. Share Gains Contribute To Dow's 261-Point Jump